SCHEMBL3259692

SCHEMBL3259692

CC(=O)OC[C@H]1O[C@@H](n2cnc3c(N)ncnc32)C[C@@H]1O

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 1/20 0.65
ENPP1 P22413 3/20 0.64
P2RY1 P47900 2/20 0.64
HIF1A Q16665 1/20 0.53
DTYMK P23919 2/20 0.51
PDE4D Q08499 2/20 0.50
PDE3A Q14432 2/20 0.50
SMN1; SMN2 Q16637 2/20 0.50
DNPH1 O43598 1/20 0.50
PRKAB2 O43741 1/20 0.50
TRPM2 O94759 1/20 0.50
LDHA P00338 1/20 0.50
ADRB2 P07550 1/20 0.50
FBP1 P09467 1/20 0.50
SRC P12931 1/20 0.50
ADORA1 P30542 1/20 0.50
P2RY2 P41231 1/20 0.50
PRKAG1 P54619 1/20 0.50
PRKAA2 P54646 1/20 0.50
KCNH2 Q12809 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8623380 1.00 POLB (0.65) POLBENPP1P2RY1HIF1ADTYMK
SCHEMBL9233212 0.94 POLB (0.59) POLBENPP1P2RY1HIF1ADTYMK
SCHEMBL3470715 0.90 POLB (0.63) POLBENPP1P2RY1HIF1ADTYMK
SCHEMBL4625882 0.89 POLB (0.62) POLBENPP1P2RY1HIF1ADTYMK
SCHEMBL23982376 0.89 POLB (0.52) POLBENPP1P2RY1PDE4DPDE3A
SCHEMBL1889395 0.89 POLB (0.64) POLBENPP1P2RY1HIF1APDE4D
SCHEMBL8058699 0.89 POLB (0.64) POLBENPP1P2RY1HIF1ADTYMK
SCHEMBL5362841 0.88 POLB (0.51) POLBENPP1P2RY1PDE4DPDE3A
SCHEMBL6833492 0.88 POLB (0.66) POLBENPP1P2RY1HIF1ADTYMK
SCHEMBL5361698 0.88 POLB (0.51) POLBENPP1P2RY1PDE4DPDE3A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9718855-B2 Nucleosides and oligonucleotides for studies on reversal of cytotoxic and mutagenic damage of DNA and as diagnostics tools CHEMGENES CORPORATION (US) 2017-08-01 US disclosed
US-20140350234-A1 Nucleosides and Oligonucleotides for Studies on Reversal of Cytotoxic and Mutagenic Damage of DNA and as Diagnostics Tools CHEMGENES CORPORATION (US) 2014-11-27 US disclosed
US-8785619-B1 Nucleosides and oligonucleotides for studies on reversal of cytotoxic and mutagenic damage of DNA potential diagnostics tools CHEMGENES CORPORATION (US) 2014-07-22 US disclosed
US-20100028894-A1 Photographic Determination of Analytes BASECLICK GMBH (DE) 2010-02-04 US disclosed
EP-2092079-A1 PHOTOGRAPIC DETERMINATION OF ANALYTES baseclick GmbH (DE) 2009-08-26 EP disclosed
US-20090087857-A1 Molecular Beacons for DNA-Photography BASECLICK GMBH (DE) 2009-04-02 US disclosed
EP-2013363-A1 MOLECULAR BEACONS FOR DNA-PHOTOGRAPHY BASF SE (DE) 2009-01-14 EP disclosed
WO-2008055679-A1 PHOTOGRAPIC DETERMINATION OF ANALYTES BASECLICK GMBH (DE) 2008-05-15 WO disclosed
WO-2007128430-A1 MOLECULAR BEACONS FOR DNA-PHOTOGRAPHY BASF SE (DE) 2007-11-15 WO disclosed
US-7169765-B1 Acyl deoxyribonucleoside derivatives and uses thereof WELLSTAT THERAPEUTICS CORPORATION (US) 2007-01-30 US disclosed
US-6306834-B1 METHODS OF TREATING OR PREVENTING RADIATION, MUTAGEN AND SUNLIGHT-INDUCED BIOLOGICAL DAMAGE, METHODS FOR IMPROVING WOUND HEALING AND TISSUE REPAIR, COMPRISING ADMINISTERING THE COMPOSITIONS OF THE PRESENT INVENTION TO AN ANIMAL. PRO-NEURON, INC. 2001-10-23 US disclosed
US-6297222-B1 TREATING OR PREVENTING RADIATION, MUTAGEN AND SUNLIGHT-INDUCED BIOLOGICAL DAMAGE, AND METHODS FOR IMPROVING WOUND HEALING AND TISSUE REPAIR PRO-NEURON, INC. 2001-10-02 US disclosed
US-6103701-A ADMINISTERING COMPOSITIONS COMPRISING ACYL DERIVATIVES OF 2'-DEOXYRIBONUCLEOSIDES; FOR IMPROVING WOUND HEALING AND TISSUE REPAIR VON BORSTEL REID WARREN (US) 2000-08-15 US disclosed
US-6020322-A Acyl deoxyribonucleoside derivatives and uses thereof PRO-NEURON, INC. (US) 2000-02-01 US disclosed
US-5756704-A Nucleosides and nucleoside derivatives containing enzymatically cleavable protecting groups BOEHRINGER MANNHEIM GMBH (DE) 1998-05-26 US disclosed
US-5677441-A Nucleosides, nucleotides and oligonucleotides containing enzymatically cleavable protecting groups BOEHRINGER MANNHEIM GMBH (DE) 1997-10-14 US disclosed
EP-0355131-B1 ACYL DEOXYRIBONUCLEOSIDE DERIVATIVES AND USES THEREOF PRO NEURON INC (US) 1996-09-04 EP disclosed
EP-0712629-A1 Acyl deoxyribonucleoside derivatives and uses thereof PRO-NEURON, INC. (US) 1996-05-22 EP disclosed
EP-0355131-A1 ACYL DEOXYRIBONUCLEOSIDE DERIVATIVES AND USES THEREOF PRO-NEURON, INC. (US) 1990-02-28 EP disclosed
US-4078139-A Process for deoxygenating secondary alcohols SCHERING CORPORATION (US) 1978-03-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140350234-A1 Nucleosides and Oligonucleotides for Studies on Reversal of Cytotoxic and Mutagenic Damage of DNA and as Diagnostics Tools UNG, OGG1, ADAR POLB 7/4885ENPP1 197/4885P2RY1 2422/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.